Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1 monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.
Welcome to BeiMedPlus
BeiGene's medical website with resources for healthcare professionals and disease information for patients and caregivers.
Please confirm the option below that best describes you so we can direct you to appropriate resources and information.